AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractImprovements in conventional cytotoxic treatment have probably reached a plateau for the treatment of lung cancer; therefore, new treatment strategies that are based on a better understanding of tumour biology are required. Some progress has been made for non-small cell lung cancer, in which erlotinib (Tarceva, OSI-774; Genentech), an epidermal growth factor receptor antagonist, has demonstrated a significant clinical benefit in a Phase III randomised trial, and has been licensed for second- or third-line treatment. Other therapies under investigation include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors and c-Kit antagonists. In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed.
CitationPerspectives on novel therapies for bronchial carcinoma. 2005, 6 (7):1157-67 Expert Opin Pharmacother
JournalExpert Opinion on Pharmacotherapy
- Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
- Authors: Mu XY, Dong XL, Sun J, Ni YH, Dong Z, Li XL, Sun EL, Yi Z, Li G
- Issue date: 2014
- [New biological treatments for lung cancer].
- Authors: Zalcman G, Richard N, Bergot E
- Issue date: 2007 Feb
- [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
- Authors: Pérol M
- Issue date: 2006 Feb
- Targeted therapy in advanced non-small-cell lung cancer.
- Authors: Gettinger S
- Issue date: 2008 Jun
- Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
- Authors: Pakkala S, Ramalingam SS
- Issue date: 2009 Mar